Evolva Holding (EVE) AI Stock Analysis

• Market Cap: CHF8.19M
• Dividend Yield: N/A
• Average Volume (3M): 33.27K
• Price to Earnings (P/E): 7.8
• Beta (1Y): 0.14
• Revenue Growth: -100.00%
• EPS Growth: N/A
• Country: CH
• Employees: 49
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 7,230,626
• 10 Day Avg. Volume: 11,831
• 30 Day Avg. Volume: 33,273
• PEG Ratio: 0.30
• Price to Book (P/B): 0.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: ―

Evolva Holding's overall stock score reflects its financial struggles with volatile revenue and negative cash flows, despite a robust balance sheet with no debt. The technical indicators show a neutral to bearish trend, lacking strong momentum. However, the valuation suggests potential undervaluation given the low P/E ratio, which slightly uplifts the overall score.

Evolva Holding Business Overview & Revenue Model

Company Description

Evolva Holding (EVE) is a Swiss-based biotechnology company focused on the research, development, and commercialization of innovative ingredients derived from nature. The company leverages advanced biosynthesis technology to produce high-value compounds for use in various sectors, including food, cosmetics, and personal care. Evolva's core products are sustainable and environmentally friendly alternatives to traditional ingredients, offering enhanced performance and value.

How the Company Makes Money

Evolva makes money primarily through the sale of its biosynthesized ingredients to businesses in the food, beverage, flavor, fragrance, and personal care industries. The company operates on a B2B model, partnering with major companies to incorporate its ingredients into their products. Revenue streams include direct sales of ingredients, licensing agreements, and long-term partnerships with key industry players. Evolva benefits from its proprietary biotechnology platform, which allows for efficient, scalable production of high-quality, sustainable compounds. Additionally, the company may earn income through research and development collaborations and grants, contributing to its overall revenue.

Evolva Holding Financial Statement Overview

Summary

Evolva Holding presents a mixed financial picture. While the company has improved certain profitability metrics and maintains a solid equity base with zero debt, its revenue volatility and negative cash flows pose significant challenges. The company must focus on stabilizing revenue streams and improving cash flow management to enhance financial health and investor confidence.

Income Statement

Evolva Holding shows a volatile income statement with significant fluctuations in revenue and profitability. The company experienced substantial revenue decline in 2024 with no reported revenue, compared to 2023. Despite improvements in EBIT and EBITDA margins in 2024, net profit margin remains a challenge with inconsistent profitability. The overall trajectory indicates potential recovery but significant instability in revenue generation.

Balance Sheet

Evolva Holding's balance sheet reveals a strong equity position with zero debt in 2024, resulting in a favorable debt-to-equity ratio. The company's equity ratio is robust, indicating financial stability. However, the declining total assets over the years is a concern, reflecting potential asset management issues.

Cash Flow

The cash flow analysis shows Evolva Holding's struggle with negative operating cash flows, although there was a significant reduction in free cash flow negative value in 2024. The company has managed its financing activities well, with limited reliance on new debt. However, the persistent negative free cash flow and operating cash flow to net income ratio highlight ongoing cash management challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	9.44M	15.54M	9.88M	7.54M
Gross Profit	0.00	-2.58M	-8.89M	-15.57M	-2.24M
EBITDA	3.70M	-98.36M	-34.52M	-31.82M	-20.60M
Net Income	1.04M	-105.23M	-43.37M	-41.27M	-29.87M
Balance Sheet
Total Assets	7.54M	9.83M	131.01M	156.17M	166.89M
Cash, Cash Equivalents and Short-Term Investments	6.75M	5.84M	5.14M	11.00M	19.67M
Total Debt	0.00	0.00	15.06M	10.84M	9.02M
Total Liabilities	945.30K	4.28M	24.77M	24.40M	21.80M
Stockholders Equity	6.60M	5.55M	106.24M	131.77M	145.09M
Cash Flow
Free Cash Flow	-2.44M	-9.72M	-21.13M	-33.57M	-28.97M
Operating Cash Flow	-2.44M	-9.25M	-18.88M	-29.79M	-23.36M
Investing Cash Flow	3.52M	15.95M	-1.76M	-4.64M	-5.60M
Financing Cash Flow	-163.10K	-5.97M	14.77M	25.72M	8.86M

Evolva Holding Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:EVE, the sentiment is Negative. The current price of 1.14 is below the 20-day moving average (MA) of 1.15, above the 50-day MA of 1.14, and above the 200-day MA of 1.05, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 49.30 is Neutral, neither overbought nor oversold. The STOCH value of 44.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:EVE.

Evolva Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NWRN	60 Neutral	$135.54M	9.47		―	450.19%	―
EVE	52 Neutral	CHF8.19M	7.80	16.81%	―	-100.00%	―
RLF	50 Neutral	CHF27.29M	―	-38.10%	―	39.52%	83.79%
MOLN	47 Neutral	CHF124.96M	―	-40.40%	―	-66.82%	4.14%
Sector *	46 Neutral	C$189.62M	-4.26	-8.56%	3.09%	13.57%	-1.98%
SANN	39 Underperform	CHF154.00M	2.58	-93.91%	―	-62.17%	-166.33%